Amarantus Bioscience Holdings Inc (AMBS)

[MagicCap]

Wake me up when this hits $100 Million market cap. I've been saying it for 6 weeks now and I will say it again. Those people who are patient enough to wait out these dips will be very wealthy when it hits $0.40+.

Here are the things to keep in mind as people bash it:

(1) 1/8/13 conference will be a major catalyst. Having the founder of a $67 billion company presenting on your behalf about the commercial opportunities of your drug should add just a teeny weeny amount of credibility.

(2) The co-founder of Amgen said MANF "could be one of the biggest successes that I have ever seen." This is a 79 year old man that has seen a lot of things in his career.

(3) Hermo Pharma, a MJFF grant recipient and VC backed, felt compelled to challenge the company's MANF patents...why? Read this article below:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."

(4) AMBS is only worth $17 Million right now. It is producing far better results than GDNF which was purchased by Amgen for $250 Million.

(5) While AMBS hasn't done head to head comarisons with Neurturin, Neurturin is being developed as a gene therapy by Ceregene and has multiple published studies comparing it with GDNF. One thing of note with Neurturin is that it has higher heparin binding, and thus less volume of diffusion in the brain. As we know GDNF had issues with volume of diffusion in the brain and MANF has been proven to have much better diffusion volume. Ceregene has plowed $150 Million into Neurturin.

Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Anyone that is patient enough to sit through these pockets of weakness will make out like bandits. I fully expect a funding partnership with a licensing deal very soon.